The use of pembrolizumab alone, or in combination with chemotherapy, as well as atezolizumab plus chemotherapy, is recommended for stage IV non-small-cell lung cancer patients without driver alterations (EGFR or ALK) according to the American Society of Clinical Oncology and Ontario Health joint guideline (12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.